EYPT Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -278.99% compared to EyePoint Pharmaceuticals's net margin of -101870.49%. EyePoint Pharmaceuticals's return on equity of -50.67% beat Editas Medicine's return on equity of -74.59%.

EyePoint Pharmaceuticals has a consensus price target of $33.45, signalling upside risk potential of 369.87%. On the other hand Editas Medicine has an analysts' consensus of -- which suggests that it could grow by 179.9%. Given that EyePoint Pharmaceuticals has higher upside potential than Editas Medicine, analysts believe EyePoint Pharmaceuticals is more attractive than Editas Medicine.

EyePoint Pharmaceuticals has a beta of 1.455, which suggesting that the stock is 45.456% more volatile than S&P 500. In comparison Editas Medicine has a beta of 1.864, suggesting its more volatile than the S&P 500 by 86.439%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $10.5M, which are larger than Editas Medicine quarterly revenues of $61K. EyePoint Pharmaceuticals's net income of -$29.4M is higher than Editas Medicine's net income of -$62.1M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 7.90x versus 1.74x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -278.99% compared to EyePoint Pharmaceuticals's net margin of 36.03%. EyePoint Pharmaceuticals's return on equity of -50.67% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

EyePoint Pharmaceuticals has a consensus price target of $33.45, signalling upside risk potential of 369.87%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 50.04%. Given that EyePoint Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe EyePoint Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.455, which suggesting that the stock is 45.456% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $10.5M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. EyePoint Pharmaceuticals's net income of -$29.4M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 7.90x versus 5.83x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of -278.99% compared to EyePoint Pharmaceuticals's net margin of -246.3%. EyePoint Pharmaceuticals's return on equity of -50.67% beat Regenxbio's return on equity of -69.62%.

EyePoint Pharmaceuticals has a consensus price target of $33.45, signalling upside risk potential of 369.87%. On the other hand Regenxbio has an analysts' consensus of $37.64 which suggests that it could grow by 393.27%. Given that Regenxbio has higher upside potential than EyePoint Pharmaceuticals, analysts believe Regenxbio is more attractive than EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.455, which suggesting that the stock is 45.456% more volatile than S&P 500. In comparison Regenxbio has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.251%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $10.5M, which are smaller than Regenxbio quarterly revenues of $24.2M. EyePoint Pharmaceuticals's net income of -$29.4M is higher than Regenxbio's net income of -$59.6M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 7.90x versus 4.32x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -278.99% compared to EyePoint Pharmaceuticals's net margin of --. EyePoint Pharmaceuticals's return on equity of -50.67% beat Cassava Sciences's return on equity of --.

EyePoint Pharmaceuticals has a consensus price target of $33.45, signalling upside risk potential of 369.87%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4815.25%. Given that Cassava Sciences has higher upside potential than EyePoint Pharmaceuticals, analysts believe Cassava Sciences is more attractive than EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.455, which suggesting that the stock is 45.456% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.856, suggesting its less volatile than the S&P 500 by 185.551%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $10.5M, which are larger than Cassava Sciences quarterly revenues of --. EyePoint Pharmaceuticals's net income of -$29.4M is lower than Cassava Sciences's net income of -$27.9M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 7.90x versus 2.59x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.